| __timestamp | Catalent, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 9335772 |
| Thursday, January 1, 2015 | 337300000 | 12390000 |
| Friday, January 1, 2016 | 358100000 | 25602000 |
| Sunday, January 1, 2017 | 402600000 | 21262000 |
| Monday, January 1, 2018 | 462600000 | 28430000 |
| Tuesday, January 1, 2019 | 512000000 | 40849000 |
| Wednesday, January 1, 2020 | 577900000 | 60210000 |
| Friday, January 1, 2021 | 687000000 | 83664000 |
| Saturday, January 1, 2022 | 844000000 | 104097000 |
| Sunday, January 1, 2023 | 831000000 | 106916000 |
| Monday, January 1, 2024 | 935000000 |
Unleashing the power of data
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. Catalent, Inc. and Iovance Biotherapeutics, Inc. offer a fascinating study in contrasts when it comes to their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Catalent's SG&A expenses have surged by approximately 180%, reflecting its aggressive expansion and operational scaling. In contrast, Iovance Biotherapeutics, while showing a significant increase of over 1,000% in the same period, started from a much smaller base, highlighting its rapid growth phase.
Interestingly, 2023 marks a year where Catalent's expenses slightly dipped, while Iovance continued its upward trajectory. This divergence underscores the different strategic paths these companies are navigating in the competitive biotech arena.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights
Zoetis Inc. or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Merus N.V. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Iovance Biotherapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. vs Xencor, Inc.: SG&A Expense Trends